MedPath

Brensocatib

Generic Name
Brensocatib
Drug Type
Small Molecule
Chemical Formula
C23H24N4O4
CAS Number
1802148-05-5
Unique Ingredient Identifier
25CG88L0BB
Background

Brensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).

Indication

用于非囊性纤维化支气管扩张症（NCFBE）成人患者的治疗。

Clinical Trials
Related News

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Conditions
Non-Cystic Fibrosis Bronchiectasis
First Posted Date
2022-04-25
Last Posted Date
2025-02-28
Lead Sponsor
Insmed Incorporated
Registration Number
NCT05344508

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Phase 2
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: Placebo
First Posted Date
2021-10-25
Last Posted Date
2023-11-01
Lead Sponsor
Insmed Incorporated
Target Recruit Count
29
Registration Number
NCT05090904
Locations
🇺🇸

USA001, Gainesville, Florida, United States

🇺🇸

USA016, Augusta, Georgia, United States

🇺🇸

USA006, Cleveland, Ohio, United States

and more 11 locations

STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19

Phase 3
Completed
Conditions
Covid19
Interventions
Drug: Placebo
First Posted Date
2021-03-26
Last Posted Date
2023-08-22
Lead Sponsor
University of Dundee
Target Recruit Count
406
Registration Number
NCT04817332
Locations
🇬🇧

Frimley Health NHS Foundation Trust, Frimley, United Kingdom

🇬🇧

Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom

🇬🇧

NHS Fife, Dunfermline, United Kingdom

and more 13 locations

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 3
Completed
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Drug: Placebo
First Posted Date
2020-10-20
Last Posted Date
2024-11-12
Lead Sponsor
Insmed Incorporated
Target Recruit Count
1767
Registration Number
NCT04594369
Locations
🇺🇸

USA039, Kissimmee, Florida, United States

🇺🇸

USA029, Newport Beach, California, United States

🇺🇸

USA103, Plantation, Florida, United States

and more 370 locations

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 2
Completed
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Drug: Placebo
First Posted Date
2017-07-17
Last Posted Date
2023-03-27
Lead Sponsor
Insmed Incorporated
Target Recruit Count
256
Registration Number
NCT03218917
Locations
🇧🇬

MHAT "Dr IvanSeliminski"-Sliven, Sliven, Bulgaria

🇧🇬

Cardioart Medical Center, Stara Zagora, Bulgaria

🇩🇰

Sjællands Universitetshospital, Roskilde, Roskilde, Denmark

and more 105 locations

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2016-01-12
Last Posted Date
2018-02-23
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT02653872
Locations
🇬🇧

Research Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy